Zymeworks Stock Price - ZYME

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Zymeworks Inc ZYME NYSE Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.00% 25.50 0.00 0.00 0.00 25.50 03:59:48
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Zymeworks Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 1.00B 39.26M $ -36.56M -1.27 - 39.18M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
596.36k $ - 0.00% - -

more financials information »

Zymeworks News

Loading Messages....

Latest ZYME Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ZYME Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week24.0927.1923.7325.6411289k1.415.85%
1 Month24.327.1921.5224.4669170k1.24.94%
3 Months18.3227.1917.622.4331296k7.1839.19%
6 Months1527.1914.0520.5503213k10.570.00%
1 Year14.1927.1910.7218.3226165k11.3179.70%
3 Years13.5296.2517.1509106k1288.89%
5 Years13.5296.2517.1509106k1288.89%

Zymeworks Description

Zymeworks Inc is a clinical-stage ccompany. It is dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The company's product candidate, ZW25, is a bispecific (dual-targeting) antibody being evaluated in an adaptive Phase 1 clinical trial, targeting two distinct domains of the human epidermal growth factor receptor 2, or HER2. Its design enables ZW25 to address patient populations with all levels of HER2 expression, including those with low to intermediate HER2-expressing tumors, who are otherwise limited to chemotherapy or hormone therapy.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.